Tirzepatide, the active pharmaceutical ingredient for Mounjaro and Zepbound, increased in popularity by 373% in one year. These four medications are all glucagon-like peptide-1 receptor agonists; and Zepbound is also a glucose-dependent insulinotropic polypeptide.
GLP-1s, which are approved for Type 2 diabetes, weight loss and cardiovascular problems, are part of a booming industry. The manufacturer of Ozempic and Mounjaro, Novo Nordisk, recently became and has remained Europe’s most valuable public company.
The research calculated healthcare drug expenditure among three factors: a drug’s list price, newly approved drugs and utilization.
The top 25 drugs ranked by U.S. expenditure in 2023, according to the study:
1. Semaglutide — $38.6 billion (100.1% change from 2022)
2. Adalimumab — $35.3 billion (9.1% change)
3. Apixaban — $22.1 billion (17.1% change)
4. Dulaglutide — $16.3 billion (5.1% change)
5. Empagliflozin — $15.9 billion (34% change)
6. Ustekinumab — $15.9 billion (14% change)
7. Pembrolizumab — $15.4 billion (19.1% change)
8. Tirzepatide — $13.2 billion (373.1% change)
9. Bictegravir/emtricitabine/tenofovir alafenamide — $13.2 billion (14.2% change)
10. Dupilumab — $11.5 billion (44.9% change)
11. Risankizumab — $10.1 billion (106.3% change)
12. Etanercept — $9.5 billion (6.9% change)
13. Insulin glargine — $8.9 billion (-4.6% change)
14. Rivaroxaban — $8.3 billion (1.9% change)
15. Dapagliflozin — $7.9 billion (41.8% change)
16. Immune globulin — $6.3 billion (2.5% change)
17. Insulin aspart — $5.8 billion (-3.5% change)
18. Secukinumab — $5.7 billion (8.6% change)
19. Sitagliptin — $5.7 billion (-9.4% change)
20. Fluticasone/umeclidinium bromide/vilanterol — $5.7 billion (28.8% change)
21. Nivolumab — $5.4 billion (9.8% change)
22. Lisdexamfetamine — $5.4 billion (15% change)
23. Insulin lispro — $5.3 billion (-1.8% change)
24. Ixekizumab — $5.3 billion (16.1% change)
25. Ocrelizumab — $5.3 billion (11% change)
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
